
    
      The study has 3 main phases:

      Induction Phase:

      Pembrolizumab I.V. infusion every 3-4 weeks for 2 doses (starting first week of HDI
      administration) given concurrently with HDI I.V. x 5 consecutive days out of 7 every week for
      4 weeks, followed by S.C. every other day 3 times each week for 2 weeks.

      This is followed by definitive surgery (week 6-8).

      Maintenance Phase (following recovery from surgery):

      Pembrolizumab I.V. infusion every 3 weeks given concurrently with HDI S.C. QOD TIW every week
      for 46 additional weeks.
    
  